Providing market research reports, industry analysis, company profiles and country reports for strategic planning, competitive intelligence, marketing and business research.
Search for Market Research Reports:    

Special Report: 2009 Chartbook of International Pharmaceutical Prices

Published by: Decision Resources

Published: Jun. 23, 2009 - 72 Pages


Table of Contents


Executive Summary

Strategic Considerations

Stakeholder Implications

Overview

Overall Price Differentials Among Markets

Pricing Hierarchy in Individual Markets

Price Variations by Therapeutic Area

Cardiovascular Drugs

Metabolic Disease Therapies

Immune and Infl ammatory Disease Therapies

Infectious Disease Therapies

Neurology Drugs

Psychiatric Drugs

Antineoplastic Drugs

Treatments for the Side Effects of Chemotherapy

Gastrointestinal Drugs

Genitourinary Drugs

Prices of Biologics

Outlook and Implications for the Pharmaceutical Industry

Impact of Health Reform in the United States

Increasing Cost-Containment Pressures in Europe

Calls for Reform of the Pricing and Reimbursement System in Japan

Innovative Approaches to Pricing and Reimbursement

Tables

1. Dosages Used for Pricing Calculations

2. Ex-Manufacturer Prices of Select Best-Selling Prescription Drugs Expressed as a Percentage of U.S. Prices

3. U.S. Prices as a Percentage of Average Prices in the Other Six Major Pharmaceutical Markets

4. French Prices as a Percentage of U.S. Prices

5. German Prices as a Percentage of U.S. Prices

6. Italian Prices as a Percentage of U.S. Prices

7. Spanish Prices as a Percentage of U.S. Prices

8. U.K. Prices as a Percentage of U.S. Prices

9. Average European Prices as a Percentage of U.S. Prices

10. Japanese Prices as a Percentage of U.S. Prices

11. Prices of Leading Cardiovascular Drugs in the Major Markets as a Percentage of U.S. Prices

12. Prices of Leading Metabolic Disease Therapies in the Major Markets as a Percentage of U.S. Prices

13. Prices of Leading Immune and Infl ammatory Disease Therapies in the Major Markets as a Percentage of U.S. Prices

14. Prices of Leading Infectious Disease Therapies in the Major Markets as a Percentage of U.S. Prices

15. Prices of Leading Neurological Disease Therapies in the Major Markets as a Percentage of U.S. Prices

16. Prices of Leading Psychiatric Drugs in the Major Markets as a Percentage of

U.S. Prices

17. Prices of Leading Antineoplastic Drugs in the Major Markets as a Percentage of

U.S. Prices

18. Prices of Leading Treatments for the Side Effects of Chemotherapy in the Major Markets as a Percentage of U.S. Prices

19. Prices of Leading Gastrointestinal Drugs in the Major Markets as a Percentage of U.S. Prices

20. Prices of Leading Genitourinary Drugs in the Major Markets as a Percentage of U.S. Prices

21. Prices of Leading Biologics in the Major Markets as a Percentage of U.S. Prices

Figures

1. Average Pharmaceutical Prices in the Major Markets as a Percentage of U.S. Prices

2. Average Prices of Leading Cardiovascular Drugs in the Major Markets as a Percentage of U.S. Prices

3. Average Prices of Leading Metabolic Disease Therapies in the Major Markets as a Percentage of U.S. Prices

4. Average Prices of Leading Immune and Infl ammatory Disease Therapies in the Major Markets as a Percentage of U.S. Prices

5. Average Prices of Leading Infectious Disease Therapies in the Major Markets as a Percentage of U.S. Prices

6. Average Prices of Leading Neurological Disease Therapies in the Major Markets as a Percentage of U.S. Prices

7. Average Prices of Leading Psychiatric Disease Therapies in the Major Markets as

a Percentage of U.S. Prices

8. Average Prices of Leading Antineoplastic Drugs in the Major Markets as a Percentage of U.S. Prices

9. Average Prices of Leading Treatments for the Side Effects of Chemotherapy in the Major Markets as a Percentage of U.S. Prices

10. Average Prices of Leading Gastrointestinal Drugs in the Major Markets as a Percentage of U.S. Prices

11. Average Prices of Leading Genitourinary Drugs in the Major Markets as a Percentage of U.S. Prices

12. Average Prices of Leading Biologics, Small-Molecule Drugs, and Pharmaceuticals Overall in the Major Markets as a Percentage of U.S. Prices

Abstract

Introduction

Payers in all countries are increasing their pressure on manufacturers to cut prices. But prescription drug pricing and reimbursement policies vary markedly among the leading pharmaceutical markets, so, to best determine pricing, pharmaceutical companies need to be aware of international price differentials. This report, featuring 33 data-rich tables and fi gures, provides comparisons of ex-manufacturer prices for 170 best-selling drugs in seven major markets and by select therapeutic area.

Questions Answered in This Report
  • In 2008, European prescription drug prices averaged just 61% of U.S. prices. How did prices vary among
    • the fi ve leading European markets? Which therapeutic areas had the highest and lowest prices relative to U.S. prices?
  • Japanese drug prices averaged 67% of U.S. prices in 2008. How many drugs were more expensive in Japan
    • than in the United States? What impact did the most recent biennial price revision have on drug prices on Japan?
  • The percentage price differential between the United States and other leading pharmaceutical markets is generally
    • much narrower for biologics than for small-molecule drugs. How do European and Japanese prices for monoclonal antibodies compare with prices in the United States? How great is the percentage price differential for recombinant proteins?
  • Payers in all markets will be looking to increase pressure on manufacturers to moderate prescription drug
    • prices. How is the U.S. government’s health reform agenda likely to impact drug prices in the United States? What methods are European governments using to control pharmaceutical prices? What changes to the Japanese pricing system are currently under discussion?
Scope
  • Overall price differentials among markets: ex-manufacturer prices of 170 best-selling drugs in six
    • major markets (France, Germany, Italy, Spain, United Kingdom, Japan) relative to U.S. prices.
  • Pricing hierarchy in individual markets: U.S. price of each of the 170 drugs under review as a
    • percentage of average prices in the six other markets under review; pricing hierarchy in individual European markets, Japan, and the fi ve European markets overall as a percentage of U.S. prices.
  • Price variations by therapeutic area: price variations among the 170 drugs in our analysis divided
    • into ten categories: cardiovascular, metabolic disease, immune and infl ammatory disease, infectious disease, neurology, psychiatry, antineoplastic drugs, treatments for the side effects of chemotherapy, gastrointestinal, and genitourinary.
  • Prices of biologics: prices as a percentage of U.S. prices for 23 biologics (9 monoclonal antibodies
    • and 14 recombinant proteins) in the six other markets under study.
  • Outlook and implications: implications of the new U.S. administration’s health reform agenda for
    • drug prices in the United States; ongoing strict government control of drug prices in Europe; industry calls for pricing reform in Japan.


Get Full Details About This Report >>
US: 800.298.5699
Int'l: +1.240.747.3093
Buy this Report

Price and Delivery Options
See related reports or call the number above for help from a research specialist.


 

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 250,000 market research reports, company profiles and country profiles from over 650 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

 

© MarketResearch.com 2009